JAZZ Q4 2024 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$12B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.1B+7.5% YoY

Gross Profit

$959M88.2% margin

Operating Income

$191M17.5% margin

Net Income

$191M17.6% margin

EPS (Diluted)

$3.11

QoQ Revenue Growth

+3.1%

Cash Flow

Operating Cash Flow

$399M

Free Cash Flow

$385M

Stock-Based Comp.

$70M

Balance Sheet

Total Assets

$12.0B

Total Liabilities

$7.9B

Stockholders' Equity

$4.1B

Cash & Equivalents

$2.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.1B	$1.0B	+7.5%
Gross Profit	$959M	$905M	+6.1%
Operating Income	$191M	$122M	+55.7%
Net Income	$191M	$94M	+103.0%

Revenue Segments

Xywav

$401M37%

Epidiolex/Epidyolex

$275M25%

Rylaze/Enrylaze

$101M9%

Zepzelca

$78M7%

Defitelio/Defibrotide

$58M5%

High Sodium AG Oxybate Product Royalty Revenue

$55M5%

Vyxeos

$53M5%

Xyrem

$49M5%

Sativex

$5M0%

Other Products

$3M0%

Geographic Segments

UNITED STATES

$974M89%

Europe

$82M8%

Other Countries

$33M3%